Core Insights - IMU Biosciences has appointed Dr. Carlos Paya as Non-Executive Director, bringing extensive experience in biopharmaceuticals and drug development [1][3] - The company aims to revolutionize the understanding, diagnosis, and treatment of immune-related diseases through advanced immune profiling and AI analytics [4][5] Company Overview - IMU Biosciences focuses on decoding the human immune system to improve health outcomes, leveraging the world's largest immune dataset for insights into immune variation and disease association [5][6] - The company was established by a team of immune specialists and technologists based on a decade of research at King's College London and the Francis Crick Institute [7] Leadership and Expertise - Dr. Carlos Paya has held significant leadership roles in various biopharmaceutical companies and has a strong background in drug discovery and commercialization [2][3] - The CEO of IMU Biosciences, Dr. John Baker, emphasizes the importance of Dr. Paya's insights for advancing the company's proprietary immune profiling platform [3]